Pacific Therapeutics Enters into Agreement with University of British Columbia to Perform Studies using Lead Candidate, PTL-101

12-Feb-2007

Pacific Therapeutics Ltd. announced that it has entered into an eight month contract with the University of British Columbia to perform animal studies with the company's lead candidate PTL-101.

The work will be conducted by Dr. Nasreen Khalil, MD, PhD, FRCPC, and FCCP. Dr. Khalil is an Associate Professor of Medicine at The University of British Columbia. In addition to her research activities Dr. Khalil has an active respirology clinic at the Vancouver Hospital Lung Centre. According to the company, she was the first scientist to describe the association of TGF-B1 with the pathogenesis of pulmonary fibrosis. In addition Dr. Khalil was the first scientist to demonstrate an aberrant expression of TGF-B1 by epithelial cells of lungs in patients with the deadly disease, idiopathic pulmonary fibrosis (IPF). At present there is no effective treatment for chronic lung transplant rejection, IPF and other progressive fibrotic diseases.

Under the contract Dr. Khalil and her team will be conducting experiments to provide data for the filing of an investigational New Drug Application (IND) with the US Food and Drug Administration. Partial funding for his research has been granted to Dr. Khalil from the Canadian Institutes of Health Research (CIHR) under the Proof of Principal II program (POP II).

Other news from the department science

Most read news

More news from our other portals

Fighting cancer: latest developments and advances

Last viewed contents

Blood protein may hold key to stopping tumor growth in cancer patients

OGT founder Professor Sir Ed Southern awarded the 2011 MRC Millennium Medal - Pioneer of DNA microarray technology recognised for outstanding impact in the field of genetic analysis

OGT founder Professor Sir Ed Southern awarded the 2011 MRC Millennium Medal - Pioneer of DNA microarray technology recognised for outstanding impact in the field of genetic analysis

Xenomics Names Research Oncologist and Biotechnology Executive Dr. David Sidransky to Board of Directors

Sartorius closes acquisition of selected assets of Danaher Life Sciences - Broadens portfolio for the development and production of biotech medicines

Sartorius closes acquisition of selected assets of Danaher Life Sciences - Broadens portfolio for the development and production of biotech medicines

EMA starts rolling review of COVID-19 vaccine Vidprevtyn - Protein-based vaccine developed by Sanofi Pasteur

EMA starts rolling review of COVID-19 vaccine Vidprevtyn - Protein-based vaccine developed by Sanofi Pasteur

Researchers use sugar to halt esophageal cancer in its tracks

Anika Therapeutics Announces Termination of Worldwide Development and Commercialization Partnership with OrthoNeutrogena - Company Files Pre-Market Approval Applicaton for Cosmetic Tissue Augmentation Product

Scottish Life Sciences Sector set to Benefit from South Korean Institute Opening in Glasgow

Endotis Pharma forms a strategic alliance with Catalent Pharma Solutions for the development of synthetic oligosaccharides

MedMira Reaches Funding Agreement to Enable US Market Expansion

Oral Multi-Kinase Inhibitor SB1317, Enters Phase 1 Clinical Trial in Advanced/Refractory Hematologic Malignancies

Abbott and Biotest Announce Global Agreement to Develop and Commercialize Novel Antibody for Autoimmune Diseases - BT-061 in clinical development for the treatment of RA and psoriasis